Source: Virtual Congress 2021 – Chinese programme 2021



Rating:

Share or cite this content

Citations should be made in the following way:
W. Li (Chengdu (Sichuan), China). Radiomics in lung cancer: progress and challenges. Virtual Congress 2021 – Chinese programme 2021

Member's Comments

No comment yet.

Related content which might interest you: How to build a lung: latest advances and emerging themes in lung bioengineering Source: Eur Respir J, 52 (1) 1601355; 10.1183/13993003.01355-2016 Year: 2018 Biomarkers in early-detection of lung cancer: current concepts Source: Virtual Congress 2021 – Biomarkers in early-detection of lung cancer: current concepts Year: 2021 High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications Source: Eur Respir J 2009; 33: 489-506 Year: 2009 Challenges in molecular testing in lung cancer patients with advanced disease Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016 Modern staging in lung cancer: from the current multidisciplinary process to novel approaches Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Screening for lung cancer - Opportunities and challenges Source: Short video statement 2020 Year: 2020 New findings in the molecular biology of lung cancer: clinical application Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Modern molecular lung cancer diagnostics – how to use and interpret it wisely Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 The electronic nose: emerging biomarkers in lung cancer diagnostics Source: Breathe, 15 (4) e135; 10.1183/20734735.0309-2019 Year: 2019 The biology of lung cancer Source: Eur Respir Mon; 2009: 44: 88–105 Year: 2009 Application of ’omics technologies to biomarker discovery in inflammatory lung diseases Source: Eur Respir J 2013; 42: 802-825 Year: 2013 New and anticipated therapeutic developments in management of non-small-cell lung cancer Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer Year: 2013 Slow-growing lung cancer as an emerging entity: from screening to clinical management Source: Eur Respir J 2013; 42: 1706-1722 Year: 2013